IC 86621

• Description :

  IC 86621 is a potent DNA-dependent protein kinase (DNA-PK) inhibitor, with an IC50 of 120 nM. IC 86621 also acts as a selective and reversible ATP-competitive inhibitor.IC 86621 inhibits DNA-PK mediated cellular DNA double-strand break (DSB) repair (EC50=68 μM) . IC 86621 increases DSB-induced antitumor activity without cytotoxic effects. IC 86621 can protects rheumatoid arthritis (RA) T cells from apoptosis[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  Apoptosis; DNA-PK

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/ic-86621.html

• Purity :

  99.06

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CC(C1=CC=C(N2CCOCC2)C=C1O)=O

• Molecular Formula :

  C12H15NO3

• Molecular Weight :

  221.26

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Chandra G, et al. Improved synthesis of a DNA-dependent protein kinase inhibitor IC86621. Arch Pharm Res. 2012 Mar;35 (4) :639-45.|[2]Shao L, et al. DNA-dependent protein kinase catalytic subunit mediates T-cell loss in rheumatoid arthritis. EMBO Mol Med. 2010 Oct;2 (10) :415-27.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [404009-40-1]